Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Fludarabine in Waldenstrom's Macroglobulinemia
NCT00020800Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Sep 2001
- Primary completion
- Apr 2003
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of rituximab in Waldenstrom macroglobulinemia (WM), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Sep 2001; status: completed.
02
Drugs
rituximab
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00020800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020800.